Trial · NCT07052084
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | SOFA score comparison between the two groups | 48 hours after administration of experimental drug (H48) | Sepsis-related Organ Failure Assessment, 0 to 24 points (higher scores indicate more severe organ dysfunction) |
| Secondary | SOFA score comparison between the two groups | 120 hours after administration of experimental drug (H120) | Sepsis-related Organ Failure Assessment, 0 to 24 points (higher scores indicate more severe organ dysfunction) |
| Secondary | Mortality comparison between the two groups | 28 days after administration of experimental drug (D28) | |
| Secondary | Lactatemia decrease comparison between the two groups | Between administration of experimental drug (H0), 24 hours after (H24), and 48 hours after (H48) | |
| Secondary | Noradrenaline use comparison between the two groups | 5 days after administration of experimental drug (D5) | Maximum dose |
| Secondary | Renal function comparison between the two groups | 28 days after administration of experimental drug (D28) | Number of days alive without renal replacement therapy |
| Secondary | Respiratory function comparison between the two groups | 28 days after administration of experimental drug (D28) | Number of days alive without mechanical ventilation |
| Secondary | Occurrence of myocardial ischemia comparison between the two groups | 28 days after administration of experimental drug (D28) | |
| Secondary | Occurrence of cardiogenic shock comparison between the two groups | 28 days after administration of experimental drug (D28) | |
| Secondary | Occurrence of mesenteric ischemia comparison between the two groups | 28 days after administration of experimental drug (D28) | |
| Secondary | Occurrence of digital ischemia comparison between the two groups | 28 days after administration of experimental drug (D28) | |
| Secondary | Occurrence of atrial fibrillation comparison between the two groups | 28 days after administration of experimental drug (D28) | |
| Secondary | Occurrence of a thromboembolic event comparison between the two groups | 28 days after administration of experimental drug (D28) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07052084/registered